Source:http://linkedlifedata.com/resource/pubmed/id/19692293
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
12
|
pubmed:dateCreated |
2009-11-25
|
pubmed:abstractText |
The anticancer agent cis-diamminedichloroplatinum (cisplatin) is a first-line chemotherapeutic agent for oral cancer. Cell exposure to cisplatin is associated with increased oxidative stress and post-translational changes in components of apoptosis pathways, including p38 Mitogen-activated protein kinase (MAPK), c-Jun-NH2-kinase (JNK), and extracellular signal-regulated kinase (ERK). Peroxiredoxin (Prx) I is an oxidative stress-inducible protein expressed in many tissues and important for reducing reactive oxygen species in vivo; however, whether Prx I helps protect cells from cisplatin injury is unknown. In this report, we examined the effects of Prx I on cell sensitivity to cisplatin-induced apoptosis. Mouse embryo fibroblasts (MEFs) derived from Prx I-deficient mice showed increased cisplatin-induced apoptosis compared with wild-type MEFs. Cisplatin treatment also led to increased activation of p38 MAPK and JNK, and reduced ERK phosphorylation in Prx I-deficient MEFs compared with wild-type MEFs. Furthermore, JNK- and ERK-specific inhibitors protected the Prx I-deficient MEFs from cisplatin-induced apoptosis, but Prx I-deficient MEFs remained more sensitive than wild-type MEFs when treated with a p38 MAPK-specific inhibitor. These findings indicate that Prx I modulates the cisplatin-evoked activation of MAPKs that lead to apoptosis, and Prx I may thus represent a useful target as a protective therapy against cisplatin cytotoxicity.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Extracellular Signal-Regulated MAP...,
http://linkedlifedata.com/resource/pubmed/chemical/JNK Mitogen-Activated Protein...,
http://linkedlifedata.com/resource/pubmed/chemical/Peroxiredoxins,
http://linkedlifedata.com/resource/pubmed/chemical/p38 Mitogen-Activated Protein...
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
1368-8375
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
45
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1037-43
|
pubmed:meshHeading |
pubmed-meshheading:19692293-Animals,
pubmed-meshheading:19692293-Antineoplastic Agents,
pubmed-meshheading:19692293-Apoptosis,
pubmed-meshheading:19692293-Cisplatin,
pubmed-meshheading:19692293-Enzyme Activation,
pubmed-meshheading:19692293-Extracellular Signal-Regulated MAP Kinases,
pubmed-meshheading:19692293-JNK Mitogen-Activated Protein Kinases,
pubmed-meshheading:19692293-Mice,
pubmed-meshheading:19692293-Peroxiredoxins,
pubmed-meshheading:19692293-p38 Mitogen-Activated Protein Kinases
|
pubmed:year |
2009
|
pubmed:articleTitle |
Peroxiredoxin I plays a protective role against cisplatin cytotoxicity through mitogen activated kinase signals.
|
pubmed:affiliation |
Molecular Cellular Physiology, Life System Medical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan.
|
pubmed:publicationType |
Journal Article
|